Skip to main content
SpringerLink
Log in

Prospects for the Chemoprevention of Breast Cancer

  • Conference paper
Control of Growth Factors and Prevention of Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 25 Accesses

Abstract

Although our understanding of breast cancer has improved enormously over the last 2 decades and treatment has become more rational, progress is very slow and improvement in case survival is modest. Permutations of local surgery with and without radiotherapy have in themselves not improved the chances of long-term survival but have at least allowed us to adopt a much more conservative approach for women with the most favourable stages of disease. Adjuvant systemic therapy has not reproduced the anticipated advantages deduced from models in experimental animals. At its best, chemotherapy in the treatment of node-positive premenopausal women has demonstrated an absolute net gain of about 10% at 5 years whereas adjuvant tamoxifen for postmenopausal women has produced an absolute net benefit of about 5% at 5 years. No doubt, with the current generation of adjuvant systemic trials, additional modest gains will be discovered but, until we experience the next conceptual shift in the biological management of breast cancer which may be decades away, we have to turn to primary and secondary preventive measures in our attempts to reduce the impact of this disease on the community.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tabar L, Dean P: The control of breast cancer through mammography screening: what is the evidence. Radiol Clin North Am 1987 (25):993–1005

    PubMed  CAS  Google Scholar 

  2. Baker LH: Breast Cancer Detection Demonstration Project (BCDPP): five year summary report. Cancer 1982 (32):4–35

    Google Scholar 

  3. Breast cancer screening: Forrest Report. HMSO 1988

    Google Scholar 

  4. Skrabanek P: False premise and false promises of breast cancer screening. Lancet 1985 (ii):316–320

    Article  Google Scholar 

  5. Wright CT: Breast cancer screening: a different look at the evidence. Br J Surgery 1986 (100):594–598

    CAS  Google Scholar 

  6. Devitt JE: False alarms of breast cancer. Lancet 1989 (ii):1257–1258

    Article  Google Scholar 

  7. Lopez UT, Blackwell CW: Breast cancer detected by screening: The importance of long-term follow-up. Surgery 1989 (106):590–595

    PubMed  CAS  Google Scholar 

  8. Pritchard GA, Jones DL, Mansel RE: Lipids in breast carcinogenesis. Br J Surg 1989 (76):1069–1073

    Article  PubMed  CAS  Google Scholar 

  9. Chen J, Campbell TC, Junyao L et al: The dieting, life-styles and mortality characteristics of 65 rural populations in the Peoples Republic of China. Dir Nutritional Sciences, Cornell University 1987

    Google Scholar 

  10. Mills PK, Annegers JF, Phillips RL: Animal product consumpton and subsequent fatal heart cancer risk among Seventh Day Adventists. Am J Epidemiol 1988 (127):440–453

    PubMed  CAS  Google Scholar 

  11. Cuzick J: The prevention of breast cancer. Lancet 1988 (ii):1–6

    Google Scholar 

  12. Prentice RL, Kakar F, Hursting S et al: Aspects of the rationale for the Women’s Health Trial. JNCI 1988 (80):802–814

    PubMed  CAS  Google Scholar 

  13. Cuzick J, Wang DY, Bulbrook RO: The preventive of breast cancer. Lancet 1986 (i):83–86

    Article  Google Scholar 

  14. Jordan VC: Chemosuppression of breast cancer with tamoxifen: Laboratory evidence and future clinical investigation. Cancer Invest 1988 (6):589–595

    Article  PubMed  CAS  Google Scholar 

  15. Love RR: Tamoxifen therapy in primary breast cancer. Biology, efficacy and side effects. J Clin Oncol 1989 (7):803–815

    PubMed  CAS  Google Scholar 

  16. Gottardes MM, Jordan VC: Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987 (47):4020–4024

    Google Scholar 

  17. Fraser SCA, Brooks MD: Tamoxifen - the story so far. Br J Clin Practice 1989 (43):380–382

    CAS  Google Scholar 

  18. NATO: Controlled trial of tamoxifen as single adjuvent tamoxifen in the management of early breast cancer. Br J Cancer 1988 (57):608–611

    Article  Google Scholar 

  19. Scottish Cancer Trial Office: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987 (ii):171–175

    Google Scholar 

  20. Preliminary Analysis by the CRC Adjuvant Breast Trial Working Party: Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988 (57):604–607

    Article  Google Scholar 

  21. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancet 1985 (ii):282

    Article  Google Scholar 

  22. Powles TJ, Hardy SE, Ashley GM et al: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989 (60):126–131

    Article  PubMed  CAS  Google Scholar 

  23. Fornander T, Rutqvist LE, Cedermark B et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989 (i):117

    Article  Google Scholar 

  24. Hardell K: Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988 (ii):563

    Article  Google Scholar 

  25. Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984 (52):339–346

    Article  PubMed  CAS  Google Scholar 

  26. Brüning PF, Bonfer JMG, Hart AAM et al: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988 (58):497–499

    Article  PubMed  Google Scholar 

  27. Caleffi M, Fentiman IS, Clark GM et al: Effects of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 1988 (119):335–339

    Article  PubMed  CAS  Google Scholar 

  28. Fentiman IS, Caleffi M, Rodin B et al: Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 1989 (60):262–264

    Article  PubMed  CAS  Google Scholar 

  29. Tormey DC: Tamoxifen: Transition from the laboratory to clinical preventive chemosuppression. Cancer Invest 1988 (6):597–601

    Article  PubMed  CAS  Google Scholar 

  30. Eriksen EF, Colvard DS, Berg NJ et al: Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988 (241):84–86

    Article  PubMed  CAS  Google Scholar 

  31. Gotfredsen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984 (53):853–857

    Article  PubMed  CAS  Google Scholar 

  32. Love RR, Mazess RB, Tormey DC et al: Bone mineral density in women with breast cancer treated for at least two years with tamoxifen. Breast Cancer Res Treat 1988 (12):297–301

    Article  PubMed  CAS  Google Scholar 

  33. Türken S, Siris E, Seidin D et al: Effects of tamoxifen on spinal bone density in women with breast cancer. JNCI 1989 (81):1086–1088

    PubMed  Google Scholar 

  34. Lippman SM, Kesslet JF, Mayskens FL jr: Retinoids as preventative and therapeutic anticancer agents. Cancer Treat Rep 1987 (71):391–405

    PubMed  CAS  Google Scholar 

  35. Moon RC, Thompson HJ, Becci PJ et al: N-(4-Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in rat. Cancer Res 1979 (39):1339–1346

    PubMed  CAS  Google Scholar 

  36. Veronesi U, Costa A: Chemoprevention of contralateral breast cancer with the synthetic retinoid fenretide. Cancer Invest 1988 (6):639–641

    Article  Google Scholar 

  37. Sporn M: Retinoids. Oncology Rev 1989 (4):15–16

    Google Scholar 

  38. Costa A, Malone W, Perloff M et al: Tolerability of the synthetic retinoid fenretidine (HPR). Eur J Cancer Clin Oncol 1989 (25):805–808

    Article  PubMed  CAS  Google Scholar 

  39. Halkier-Sorensen L: Menstrual changes in a patient treated with etretinate. Eur J Cancer Clin Oncol 1987 (2):636

    CAS  Google Scholar 

  40. Filiberti A, Tamburini M, Andreoli C et al: Pyschologic aspects of patients participating in a phase I study with the synthetic 4-HPR. Tumori 1988 (74):353–356

    PubMed  CAS  Google Scholar 

  41. Keiser-Kupfer Ml, Peck GL, Caruso RC et al: Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophthalmol 1986 (104):69–76

    Google Scholar 

  42. Formelli F, Carsana R, Costa A et al: Plasma retinol reduction by the synthetic retinoid fenretinide: A one year follow-up study of breast cancer patients. Cancer Res 1989 49: in press

    Google Scholar 

  43. The Centres for Disease Control Cancer and Steroid Hormone Study. Long term oral contraceptive use and the risk of breast cancer. JAMA 1983 (249):1591–1595

    Article  Google Scholar 

  44. Wile GA, DiSaia PJ: Hormones and breast cancer. Am J Surg 1989 (157):438–442

    Article  PubMed  CAS  Google Scholar 

  45. UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet 1989 (i):973–982

    Google Scholar 

  46. Oral contraceptives and cancer. FDA Drug Bulletin 1984 14:2–3

    Google Scholar 

  47. Royal College of General Practitioners: Effects on hypertension and benign breast disease of progestagen component in combined oral contraceptive. Lancet 1977 (i):624

    Google Scholar 

  48. Colletta AA, Howell FV, Baum M: A novel binding site for a synthetic progestagen in breast cancer cells. J Steroid Biochem 1989 (33):1055–1061

    Article  PubMed  CAS  Google Scholar 

  49. Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB: The growth inhibition of human breast cancer cells by a novel synthetic progestin is partly mediated by the induction of transforming growth factor beta. Experimental Cell Research 1990: in press

    Google Scholar 

  50. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985 (312):146–151

    Article  PubMed  CAS  Google Scholar 

  51. Page DL, Dupont WD: Histopathologic risk factors for breast cancer in women with benign breast disease. Sem Surg Oncol 1988 (4):213–217

    Article  CAS  Google Scholar 

  52. Anti-platelet trialists’ collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988 (296):320–331

    Article  Google Scholar 

  53. Ratko TA, Detrisac CJ, Dinger MN et al: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 1989 (49):4472–4476

    PubMed  CAS  Google Scholar 

  54. Simpson HW, Candlish W, Pausan AW, McArdle CS, Griffiths K, Small RG: Genesis of breast cancer in the premenopause. Lancet 1988 (i):74–76

    Article  Google Scholar 

  55. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE: Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. Br J Cancer 1990 (61):298–302

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK

    Michael Baum

Authors
  1. Michael Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratory of Chemoprevention, National Cancer Institute, Building 41, Room C-629, 20892, Bethesda, MD, USA

    Michael B. Sporn

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Baum, M. (1992). Prospects for the Chemoprevention of Breast Cancer. In: Sporn, M.B. (eds) Control of Growth Factors and Prevention of Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77383-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77383-9_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77385-3

  • Online ISBN: 978-3-642-77383-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation